Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib were disclosed for patients with advanced RET fusion-positive non–small cell lung cancer. The publication is framed as disclosure information provided by authors for the manuscript, consolidating endpoint and tolerability reporting from the trial cohort(s). The final ARROW dataset adds to the evidence base for pralsetinib use in a RET-defined NSCLC population, supporting clinical decision-making and future study design around durability and safety.